Strategic Results

Our rigorous query-based approach has yielded invaluable perspectives for our clients across a range of assessments:

  • Identifying the “make-or-break” development milestones for an early-stage product candidate
  • Predicting physician prescribing practices and their sensitivity to key product and market drivers
  • Guiding investment, clinical development, licensing, and partnering decisions
  • Characterizing the future competitive environment and an early-stage product’s potential role in the treatment hierarchy
  • Identifying and prioritizing the potential indications for an early-stage technology
  • Determining the minimum commercially viable target product profile
  • Identify the commercial trade-offs of optimizing one product attribute in lieu of another
  • Developing revenue forecast models to predict market share and realistic upside and downside scenarios
  • Identifying and prioritizing the potential indications for an early-stage technology
  • Developing the clinical, reimbursement and commercial arguments to substantiate a major investment decision

“Aptis Partners have been essential in helping develop commercialization strategies and informing R&D investments. Through skillful engagement of external key influencers and strong strategic capability, they have the unique ability to uncover meaningful insights and incorporate them into actionable recommendations. We have collaborated on numerous projects, including defining market opportunities, developing target product profiles and validating commercial forecasts to inform investments from early research to late-stage development. Susan and Tucker do not merely sell the projects and deliver the presentations; they execute the work from design through interviews to analysis and recommendations. Their seasoned judgment as a trusted strategic partner is invaluable in sorting through the commercial implications of major investment decisions. Before investing in an R&D decision, I would highly recommend investing in Aptis Partners.”

Anish Patel, Senior Director, AbbVie Stemcentrx